Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models

Acta Gastro-Enterologica Belgica

Volumn 74, Issue 1, 2011, Pages 34-44

  Borbath, I ^a   Starkel P ^a  

^a UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

Author keywords

Animal models; Chemoprevention; FTS; Hepatocellular carcinoma; Lanreotide

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOPEPTIN; ANTIFIBROTIC AGENT; ANTIVIRUS AGENT; DIETHYLNITROSAMINE; FARNOQUINONE; GROWTH HORMONE; HEPATITIS B VACCINE; N (2 FLUORENYL)ACETAMIDE; OCTREOTIDE; PEGINTERFERON; PERETINOIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RETINOID; SALIRASIB; SEROTONIN; SOMATOSTATIN DERIVATIVE; TRASTUZUMAB;

ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; DISEASE MODEL; DRUG INHIBITION; DRUG MECHANISM; HUMAN; INFLAMMATION; LIPID METABOLISM; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; NONHUMAN; ONCOGENE RAS; TUMOR VOLUME; VACCINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; FARNESOL; HUMANS; HYPOGLYCEMIC AGENTS; LIVER NEOPLASMS; PEPTIDES, CYCLIC; SALICYLIC ACIDS; SOMATOSTATIN; THIAZOLIDINEDIONES;

EID: 79956267145     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. EL-SERAG H. B., RUDOLPH K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007, 132: 2557-76.
2. POLESEL J., ZUCCHETTO A., MONTELLA M., MASO L.D., CRISPO A., LA VECCHIA C., SERRAINO D., FRANCESCHI S., TALAMINI R. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann. Oncol., 2009, 20: 353-7.
3. THORGEIRSSON S.S., GRISHAM J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet., 2002, 31: 339-46.
4. KIYOSAWA K. Trend of liver cirrhosis as precancerous lesions. Hepatology Res., 2002: S40-45.
5. POON R.T., FAN S.T., NG I.O., LO C.M., LIU C.L., WONG J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer, 2000, 89: 500-7.
6. IMAMURA H., MATSUYAMA Y., TANAKA E., OHKUBO T., HASEGAWA K., MIYAGAWA S., SUGAWARA Y., MINAGAWA M., TAKAYAMA T., KAWASAKI S., MAKUUCHI M. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J. Hepatol., 2003, 38: 200-7.
7. HOSHIDA Y., VILLANUEVA A., KOBAYASHI M., PEIX J., CHIANG D.Y., CAMARGO A., GUPTA S., MOORE J., WROBEL M.J., LERNER J., REICH M., CHAN JA., GLICKMAN J.N., IKEDA K., HASHIMOTO M., WATANABE G., DAIDONE M.G., ROAYAIE S., SCHWARTZ M., THUNG S., SALVESEN H.B., GABRIEL S., MAZZAFERRO V., BRUIX J., FRIEDMAN S.L., KUMADA H., LLOVET J.M., GOLUB T.R. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med., 2008, 359: 1995-2004.
8. CHANG M.H., CHEN C.J., LAI M.S., HSU H.M., WU T.C., KONG M.S., LIANG D.C., SHAU W.Y., CHEN D.S., FOR THE TAIWAN CHILDHOOD HEPATOMA STUDY GROUP. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N. Engl. J. Med., 1997, 336: 1855-9.
9. CAMMA C., GIUNTA M., ANDREONE P., CRAXI A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J. Hepatol., 2001, 34: 593-602.
10. LOK A.S., SEEFF L.B., MORGAN T.R., DI BISCEGLIE A.M., STERLING R.K., CURTO T.M., EVERSON G.T., LINDSAY K.L., LEE W.M., BONKOVSKY H.L., DIENSTAG J.L., GHANY M.G., MORISHIMA C., GOODMAN Z.D., HALT-C TRIAL GROUP. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology, 2009, 136: 138-48.
11. YAMADA Y., SHIDOJI Y., FUKUTOMI Y., ISHIKAWA T., KANEKO T., NAKAGAMA H., IMAWARI M., MORIWAKI H., MUTO Y. Positive and negative regulations of albumin gene expression by retinoids in human hepatoma cell lines. Mol. Carcinog., 1994, 10: 151-8.
12. YASUDA I., SHIRATORI Y., ADACHI S., OBORA A., TAKEMURA M., OKUNO M., SHIDOJI Y., SEISHIMA M., MUTO Y., MORIWAKI H. Acyclic retinoid induces partial differentiation, down-regulates telomerase reverse transcriptase mRNA expression and telomerase activity, and induces apoptosis in human hepatoma-derived cell lines. J. Hepatol., 2002, 36: 660- 71.
13. MUTO Y., MORIWAKI H., NINOMIYA M., ADACHI S., SAITO A., TAKASAKI K.T., TANAKA T., TSURUMI K., OKUNO M., TOMITA E., NAKAMURA T., KOJIMA T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N. Engl. J. Med., 1996, 334: 1561-7.
14. TATEBE H., SHIMIZU M., SHIRAKAMI Y., TSURUMI H., MORIWAKI H. Synergistic growth inhibition by 9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells. Clin. Cancer Res., 2008, 14: 2806-12.
15. KANAMORI T., SHIMIZU M., OKUNO M., MATSUSHIMANISHIWAKI R., TSURUMI H., KOJIMA S., MORIWAKI H. Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells. Cancer Sci., 2007, 98: 431-7.
16. MICHALIK L., DESVERGNE B., WAHLI W. Peroxisome-proliferatoractivated receptors and cancers: complex stories. Nat. Rev. Cancer, 2004, 4: 61-70.
17. GROMMES C., LANDRETH G.E., HENEKA M.T. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol., 2004, 5: 419-29.
18. BORBATH I., HORSMANS Y. The Role of PPARgamma in Hepatocellular Carcinoma. PPAR Res., 2008, 2008: 209520.
19. PATEL Y.C. Somatostatin and its receptor family. Front. Neuroendocrinol., 1999, 20: 157-98.
20. BOUSQUET C., PUENTE E., BUSCAIL L., VAYSSE N., SUSINI C. Antiproliferative effect of somatostatin and analogs. Chemotherapy, 2001, 47 Suppl 2: 30-9.
21. PATEL Y.C. Molecular pharmacology of somatostatin receptor subtypes. J. Endocrinol. Invest., 1997, 20: 348-67.
22. HEANEY A.P., MELMED S. Molecular targets in pituitary tumours. Nat. Rev. Cancer, 2004, 4: 285-95.
23. REUBI J.C., WASER B., SCHAER J.C., LAISSUE J.A. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med., 2001, 28: 836-46.
24. SUSINI C., BUSCAIL L. Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol., 2006, 17: 1733-42.
25. SIEGEL R.A., TOLCSVAI L., RUDIN M. Partial inhibition of the growth of transplanted dunning rat prostate tumors with the long-acting somatostatin analogue sandostatin (SMS 201-995). Cancer Res., 1988, 48: 4651-5.
26. WECKBECKER G., RAULF F., STOLZ B., BRUNS C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol. Ther., 1993, 60: 245-64.
27. FROIDEVAUX S., EBERLE A.N. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers., 2002, 66: 161-83.
28. LAHLOU H., GUILLERMET J., HORTALA M., VERNEJOUL F., PYRONNET S., BOUSQUET C., SUSINI C. Molecular signaling of somatostatin receptors. Ann. N. Y. Acad. Sci., 2004, 1014: 121-31.
29. WOLTERING E.A. Development of targeted somatostatin-based anti - angiogenic therapy: a review and future perspectives. Cancer Biother. Radiopharm., 2003, 18: 601-9.
30. REYNAERT H., ROMBOUTS K., VANDERMONDE A., URBAIN D., KUMAR U., BIOULAC-SAGE P., PINZANI M., ROSENBAUM J., GEERTS A. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut, 2004, 53: 1180-9.
31. REUBI J.C., ZIMMERMANN A., JONAS S., WASER B., NEUHAUS P., LADERACH U., WIEDENMANN B. Regulatory peptide receptors in human hepatocellular carcinomas. Gut, 1999, 45: 766-74.
32. BLÄKER M., SCHMITZ M., GOCHT A., BURGHARDT S., SCHULZ M., BRÖRING D.C., PACE A., GRETEN H., DE WEERTH A. Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. J. Hepatol., 2004, 41: 112-8.
33. JIA W.D., XU G.L., XU R.N., SUN H.C., WANG L., YU J.H., WANG J., LI J.S., ZHAI Z.M., XUE Q. Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. J. Cancer Res. Clin. Oncol., 2003, 129: 327-34.
34. HAYRY P., RAISANEN A., USTINOV J., MENNANDER A., PAAVONEN T. Somatostatin analog lanreotide inhibits myocyte replication and several growth factors in allograft arteriosclerosis. Faseb. J., 1993, 7: 1055-60.
35. NOTAS G., KOLIOS G., MASTRODIMOU N., KAMPA M., VASILAKI A., XIDAKIS C., CASTANAS E., THERMOS K., KOUROUMALIS E. Cortistatin production by HepG2 human hepato - cellular carcinoma cell line and distribution of somatostatin receptors. J. Hepatol., 2004, 40: 792-8.
36. RADERER M., HEJNA M.H., MULLER C., KORNEK G.V., KURTARAN A., VIRGOLINI I., FIEBIEGER W., HAMILTON G., SCHEITHAUER W. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int. J. Oncol., 2000, 16: 1197-201.
37. ADJEI A.A. Blocking oncogenic Ras signaling for cancer therapy. J. Natl. Cancer Inst., 2001, 93: 1062-74.
38. KATO K., COX A.D., HISAKA M.M., GRAHAM S.M., BUSS J.E., DER CHANNING J. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA, 1992, 89: 6403-7.
39. CALVISI DF., LADU S., GORDEN A., FARINA M., CONNER E.A., LEE J.S., FACTOR V.M., THORGEIRSSON S.S. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology, 2006, 130: 1117-28.
40. OGATA N., KAMIMURA T., ASAKURA H. Point mutation, allelic loss and increased methylation of c-Ha-ras gene in human hepatocellular carcinoma. Hepatology, 1991, 13: 31-7.
41. GU J.R., HU L.F., CHENG Y.C., WAN D.F. Oncogenes in human primary hepatic cancer. J. Cell Physiol. Suppl., 1986, 4: 13-20.
42. RICHARDS C.A., SHORT S.A., THORGEIRSSON S.S., HUBER B.E. Characterization of a transforming N-ras gene in the human hepatoma cell line Hep G2: additional evidence for the importance of c-myc and ras cooperation in hepatocarcinogenesis. Cancer Res., 1990, 50: 1521-7.
43. YOSHIDA T., HISAMOTO T., AKIBA J., KOGA H., NAKAMURA K., TOKUNAGA Y., HANADA S., KUMEMURA H., MAEYAMA M., HARADA M., OGATA H., YANO H., KOJIRO M., UENO T., YOSHIMURA A., SATA M. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene, 2006, 25: 6056-66.
44. HAKLAI R., WEISZ M.G., ELAD G., PAZ A., MARCIANO D., EGOZI Y., BEN-BARUCH G., KLOOG Y. Dislodgment and accelerated degradation of Ras. Biochemistry, 1998, 37: 1306-14.
45. ELAD G., PAZ A., HAKLAI R., MARCIANO D., COX A., KLOOG Y. Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid. Biochim. Biophys. Acta, 1999, 1452: 228-42.
46. MAROM M., HAKLAI R., BEN-BARUCH G., MARCIANO D., EGOZI Y., KLOOG Y. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J. Biol. Chem., 1995, 270: 22263-70.
47. JANSEN B., SCHLAGBAUER-WADL H., KAHR H., HEERE-RESS E., MAYER B.X., EICHLER H., PEHAMBERGER H., GANA-WEISZ M., BEN-DAVID E., KLOOG Y., WOLFF K. Novel Ras antagonist blocks human melanoma growth. Proc. Natl. Acad. Sci. USA, 1999, 96: 14019-24.
48. WEISZ B., GIEHL K., GANA-WEISZ M., EGOZI Y., BEN-BARUCH G., MARCIANO D., GIERSCHIK P., KLOOG Y. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene, 1999, 18: 2579-88.
49. EGOZI Y., WEISZ B., GANA-WEISZ M., BEN-BARUCH G., KLOOG Y. Growth inhibition of ras-dependent tumors in nude mice by a potent rasdislodging antagonist. Int. J. Cancer, 1999, 80: 911-8.
50. REIF S., WEIS B., AEED H., GANA-WEIS M., ZAIDEL L., AVNI Y., ROMANELLI RG., PINZANI M., KLOOG Y., BRUCK R. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats. J. Hepatol., 1999, 31: 1053-61.
51. NEWELL P., VILLANUEVA A., FRIEDMAN S.L., KOIKE K., LLOVET J.M. Experimental models of hepatocellular carcinoma. J. Hepatol., 2008, 48: 858-79.
52. LEE J.S., CHU I.S., MIKAELYAN A., CALVISI D.F., HEO J., REDDY J.K. et al. Application of comparative functional genomics to identify bestfit mouse models to study human cancer. Nat. Genet., 2004, 36: 1306-11.
53. FEO F., PASCALE R.M., CALVISI D. Models for liver cancer. In: MALCOLM R.A. (ed). The cancer handbook: John Wiley & Sons, 2007, p. 1-16.
54. POIRIER L.A. Hepatocarcinogenesis by diethylnitrosamine in rats fed high dietary levels of lipotropes. J. Natl. Cancer Inst., 1975, 54: 137-40.
55. CORPECHOT C., BARBU V., WENDUM D., KINNMAN N., REY C., POUPON R., ROSMORDUC O. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology, 2002, 35: 1010-21.
56. BRALET M.P., PICHARD V., FERRY N. Demonstration of direct lineage between hepatocytes and hepatocellular carcinoma in diethylnitrosaminetreated rats. Hepatology, 2002, 36: 623-30.
57. SCHIFFER E., HOUSSET C., CACHEUX W., WENDUM D., DESBOISMOUTHON C., REY C., CLERGUE F., POUPON R., BARBU V., ROSMORDUC O. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology, 2005, 41: 307-14.
58. CHUNG Y.H., KIM J.A., SONG B.C., LEE G.C., KOH M.S., LEE Y.S., LEE S.G., SUH D.J. Expression of transforming growth factor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma. Cancer, 2000, 89: 977-82.
59. TSUJIUCHI T., TSUTSUMI M., SASAKI Y., TAKAHAMA M., KONISHI Y. Different frequencies and patterns of beta-catenin mutations in hepatocellular carcinomas induced by N-nitrosodiethylamine and a cholinedeficient L-amino acid-defined diet in rats. Cancer Res., 1999, 59: 3904-7.
60. PITOT H.C. Altered hepatic foci: their role in murine hepatocarcinogenesis. Annu. Rev. Pharmacol. Toxicol., 1990, 30: 465-500.
61. XU Y.H., CAMPBELL H.A., SATTLER G.L., HENDRICH S., MARONPOT R., SATO K., PITOT H.C. Quantitative stereological analysis of the effects of age and sex on multistage hepatocarcinogenesis in the rat by use of four cytochemical markers. Cancer Res., 1990, 50: 472-9.
62. XU Y.H., PITOT H.C. An improved stereologic method for three-dimensional estimation of particle size distribution from observations in two dimensions and its application. Comput. Methods Programs Biomed., 2003, 72: 1-20.
63. BORBATH I., LECLERCQ I., MOULIN P., SEMPOUX C., HORSMANS Y. The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver. Eur. J. Cancer, 2007, 43: 1755-63.
64. LECLERCQ I.A., SEMPOUX C., STARKEL P., HORSMANS Y. Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats. Gut, 2006, 55: 1020-9.
65. DA SILVA MORAIS A., ABARCA-QUINONES J., HORSMANS Y., STARKEL P., LECLERCQ I.A. Peroxisome proliferated-activated receptor gamma ligand, Pioglitazone, does not prevent hepatic fibrosis in mice. Int. J. Mol. Med., 2007, 19: 105-12.
66. BORBATH I., LECLERCQ I.A., ABARCA-QUINONES J., DESAEGER C., LEBRUN V., MOULIN P., SEMPOUX C., HORSMANS Y. Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotide. Cancer Sci., 2007, 98: 1831-9.
67. BORBATH I., LECLERCQ I.A., SEMPOUX C., ABARCA-QUINONES J., DESAEGER C., HORSMANS Y. Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. Chem. Biol. Interact., 2010, 183: 238-48.
68. DA SILVA MORAIS A., SALIEZ A., LECLERCQ I., HORSMANS Y., STARKEL P. Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats. Clin. Sci. (Lond.)., 2008, 114: 73- 83.
69. SCHNEIDER-MERCK T., BORBATH I., CHARETTE N., DE SAEGER C., ABARCA J., LECLERCQ I., HORSMANS Y., STÄRKEL P. The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats. Eur. J. Cancer, 2009, 45: 2050-60.
70. FORT J., OBERTI F., PILETTE C., VEAL N., GALLOIS Y., DOUAY O., ROUSSELET M.C., ROSENBAUM J., CALÈS P. Antifibrotic and hemodynamic effects of the early and chronic administration of octreotide in two models of liver fibrosis in rats. Hepatology, 1998, 28: 1525-31.
71. TSIMBERIDOU A.M., RUDEK M.A., HONG D., NG C.S., BLAIR J., GOLDSWEIG H., GOLDSWEIG H., KURZROCK R. Phase 1 first-inhuman clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemother. Pharmacol., 2009, May 31 (Epub ahead of print).
72. KOGA H., HARADA M., OHTSUBO M., SHISHIDO S., KUMEMURA H., HANADA S., TANIGUCHI E., YAMASHITA K., KUMASHIRO R., UENO T., SATA M. Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells. Hepatology, 2003, 37: 1086-96.
73. KOGA H., SAKISAKA S., HARADA M., TAKAGI T., HANADA S., TANIGUCHI E., KAWAGUCHI T., SASATOMI K., KIMURA R., HASHIMOTO O., UENO T., YANO H., KOJIRO M., SATA M. Involvement of p21WAF1/Cip1, p27Kip1, and p18INK4c in troglitazoneinduced cell-cycle arrest in human hepatoma cell lines. Hepatology, 2001, 33: 1087-97.
74. CHIANG D.Y., VILLANUEVA A., HOSHIDA Y., PEIX J., NEWELL P., MINGUEZ B., LEBLANC A.C., DONOVAN D.J., THUNG SN., SOLÉ M., TOVAR V., ALSINET C., RAMOS A.H., BARRETINA J., ROAYAIE S., SCHWARTZ M., WAXMAN S., BRUIX J., MAZZAFERRO V., LIGON A.H., NAJFELD V., FRIEDMAN S.L., SELLERS W.R., MEYERSON M., LLOVET J.M. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res., 2008, 68: 6779-88.